Ken Griffin Mersana Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$2.0 - $4.45 $9,000 - $20,025	4,500 Added 21.74%	25,200 $50,000
Q1 2024 May 15, 2024	SELL	$2.16 - $5.94 $46,872 - $128,898	-21,700 Reduced 51.18%	20,700 $92,000
Q4 2023 Feb 14, 2024	SELL	$1.11 - $2.34 $70,596 - $148,824	-63,600 Reduced 60.0%	42,400 $98,000
Q3 2023 Nov 14, 2023	SELL	$1.06 - $3.91 $58,300 - $215,050	-55,000 Reduced 34.16%	106,000 $134,000
Q2 2023 Aug 14, 2023	BUY	$3.08 - $9.55 $462,616 - $1.43 Million	150,200 Added 1390.74%	161,000 $529,000
Q1 2023 May 15, 2023	BUY	$4.0 - $7.02 $27,200 - $47,736	6,800 Added 170.0%	10,800 $44,000
Q4 2022 Feb 14, 2023	BUY	$5.65 - $7.86 $22,600 - $31,440	4,000 New	4,000 $23,000

124

114M

73.5K

46.4K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $210M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.